| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA959: Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis |
|
Medicine details |
|
| Medicine name | daratumumab (Darzalex®) |
| Formulation | 1800 mg solution for infusion |
| Reference number | 3647 |
| Indication | In combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain amyloidosis |
| Company | Janssen-Cilag Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 18/06/2021 |
| NICE guidance | |